Novavax Inc. (NASDAQ:NVAX) had its price objective trimmed by S&P Equity Research from $1.44 to $1.17 in a research note released on Friday.

Other equities analysts have also recently issued reports about the stock. Vetr cut shares of Novavax from a strong-buy rating to a buy rating and set a $7.77 price objective on the stock. in a research note on Monday, July 25th. Citigroup Inc. raised their price objective on shares of Novavax from $10.00 to $12.00 and gave the company a buy rating in a research note on Thursday, July 28th. FBR & Co set a $17.00 price objective on shares of Novavax and gave the company a buy rating in a research note on Thursday, August 11th. Guggenheim reaffirmed a buy rating and issued a $25.00 price objective on shares of Novavax in a research note on Monday, August 29th. Finally, Zacks Investment Research raised shares of Novavax from a sell rating to a hold rating in a research note on Friday, June 10th. Seven equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of Hold and an average price target of $7.06.

Novavax (NASDAQ:NVAX) opened at 1.94 on Friday. The stock has a 50 day moving average of $6.69 and a 200-day moving average of $6.16. The firm’s market capitalization is $525.42 million. Novavax has a 1-year low of $1.16 and a 1-year high of $9.56.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by $0.04. Novavax had a negative net margin of 1,405.84% and a negative return on equity of 112.45%. The business earned $2.50 million during the quarter, compared to the consensus estimate of $8.03 million. During the same period in the previous year, the business posted ($0.08) earnings per share. Novavax’s revenue was down 82.1% compared to the same quarter last year. On average, equities research analysts anticipate that Novavax will post ($1.09) earnings per share for the current year.

In other Novavax news, Director Gail Boudreaux purchased 100,000 shares of the stock in a transaction on Tuesday, September 20th. The shares were purchased at an average cost of $1.45 per share, for a total transaction of $145,000.00. Following the purchase, the director now owns 200,000 shares of the company’s stock, valued at $290,000. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 3.50% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in NVAX. Amalgamated Bank increased its position in shares of Novavax by 1.1% in the second quarter. Amalgamated Bank now owns 28,525 shares of the biopharmaceutical company’s stock worth $196,000 after buying an additional 300 shares during the period. Stifel Financial Corp increased its position in shares of Novavax by 1.9% in the second quarter. Stifel Financial Corp now owns 21,990 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 400 shares during the period. Principal Financial Group Inc. increased its position in shares of Novavax by 0.9% in the second quarter. Principal Financial Group Inc. now owns 47,560 shares of the biopharmaceutical company’s stock worth $346,000 after buying an additional 445 shares during the period. IFP Advisors Inc increased its position in shares of Novavax by 1.7% in the first quarter. IFP Advisors Inc now owns 28,296 shares of the biopharmaceutical company’s stock worth $146,000 after buying an additional 480 shares during the period. Finally, Prudential Financial Inc. increased its position in shares of Novavax by 5.7% in the second quarter. Prudential Financial Inc. now owns 27,853 shares of the biopharmaceutical company’s stock worth $202,000 after buying an additional 1,500 shares during the period. 79.84% of the stock is owned by institutional investors.

Novavax Company Profile

Novavax, Inc (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases.

5 Day Chart for NASDAQ:NVAX

Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.